Hh Zhou

Dr. Hh Zhou


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 1989 in New England Journal of Medicine
Verified
Journal Article
Closed access
HZHh Zhou
Hh Zhou
RKRichard P. Koshakji
Richard P. Koshakji
DSDavid J. Silberstein
David J. Silberstein
GWGrant R. Wilkinson
Grant R. Wilkinson
AWAlastair J.J. Wood
Alastair J.J. Wood
To determine whether the pharmacokinetics and pharmacodynamics of beta-blockade differ among racial groups, we gave 10 men of Chinese descent and 10 American white men 10, 20, 40, and 80 mg of propranolol every eight hours; the dosages were given in random order, and each dose was given for one day. The degree of beta-blockade was measured as the reduction in the heart rate and blood pressure in the supine and upright positions and during treadmill exercise testing.

Verified
Journal Article
Open access
PDF file
MBMei-Hua Bao
Mei-Hua Bao
XFXing Feng
Xing Feng
YZYi-Wen Zhang
Yi-Wen Zhang
XLXiao-Ya Lou
Xiao-Ya Lou
YCYu Cheng
Yu Cheng
HZHh Zhou
Hh Zhou
The let-7 family is the second microRNA found in C. elegans. Recent researches have found it is highly expressed in the cardiovascular system. Studies have revealed the aberrant expression of let-7 members in cardiovascular diseases, such as heart hypertrophy, cardiac fibrosis, dilated cardiomyopathy (DCM), myocardial infarction (MI), arrhythmia, angiogenesis, atherosclerosis, and hypertension. Let-7 also participates in cardiovascular differentiation of embryonic stem cells. TLR4, LOX-1, Bcl-xl and AGO1 are by now the identified target genes of let-7. The circulating let-7b is suspected to be the biomarker of acute MI and let-7i, the biomarker of DCM. Further studies are necessary for identifying the gene targets and signaling pathways of let-7 in cardiovascular diseases. Let-7 might be a potential therapeutic target for cardiovascular diseases. This review focuses on the research progresses regarding the roles of let-7 in cardiovascular development and diseases.

27 July 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JZJun Zhang
Jun Zhang
XQXia Qin
Xia Qin
BWBin Wang
Bin Wang
GXGe Xu
Ge Xu
ZQZhexue Qin
Zhexue Qin
ZZzhen zou
zhen zou
Although zinc oxide nanoparticles (ZnONPs) are widely used, they have raised concerns of toxicity in humans. Previous studies have indicated that reactive oxygen species (ROS) and autophagy are involved in the cytotoxicity of ZnONPs, but the regulatory mechanisms between autophagy and ROS remain to be elucidated. Herein, we comprehensively investigated the regulatory mechanism of autophagy and the link between autophagy and ROS in ZnONPs-treated lung epithelial cells. We demonstrated that ZnONPs could induce autophagy, and this process could enhance the dissolution of ZnONPs in lysosomes to release zinc ions. Sequentially, zinc ions released from ZnONPs were able to damage not only lysosomes, leading to impaired autophagic flux, but also mitochondria. Impaired autophagic flux resulted in the accumulation of damaged mitochondria, which could generate excessive ROS to cause cell death. We further demonstrated that the inhibition of autophagy by either pharmacological inhibitors or small interfering RNA (siRNA)-mediated knockdown of Beclin-1 and AMP-activated protein kinase could ameliorate ZnONPs-induced cell death. Moreover, we found that lysosomal-associated membrane protein 1/2 (LAMP-1/2), which were the most abundant highly glycosylated protein in late endosomes/lysosomes, exhibited aberrant expression pattern upon treatment with ZnONPs. Intriguingly, LAMP-2 knockdown, but not LAMP-1 knockdown, could exacerbate the ROS generation and cell death induced by ZnONPs treatment. Meanwhile, LAMP-2 overexpression alleviated ZnONPs-induced cell death, suggesting that LAMP-2 was linked to this toxic phenotype induced by ZnONPs. Our results indicate that autophagic dysfunction could contribute to excessive ROS generation upon treatment with ZnONPs in lung epithelial cells, suggesting that modulating the autophagy process would minimize ZnONPs-associated toxicity.

4 November 2008 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
GWGuo Wang
Guo Wang
HLHe-Ping Lei
He-Ping Lei
ZLZhi Li
Zhi Li
ZTZhi-Rong Tan
Zhi-Rong Tan
DGDong Guo
Dong Guo
HZHh Zhou
Hh Zhou

26 August 2011 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
YGYing Guo
Ying Guo
YCYao Chen
Yao Chen
ZTZhi-Rong Tan
Zhi-Rong Tan
CKCurtis D. Klaassen
Curtis D. Klaassen
HZHh Zhou
Hh Zhou

15 April 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
CLChaopeng Li
Chaopeng Li
TRTai Rao
Tai Rao
XCXiaoping Chen
Xiaoping Chen
ZZZhengsheng Zou
Zhengsheng Zou
AWAiwu Wei
Aiwu Wei
DODongsheng Ouyang
Dongsheng Ouyang